You've been prescribed BRAVELLE®, a follicle-stimulating hormone (FSH). BRAVELLE® can be administered by subcutaneous (SC) or intramuscular (IM) injections and is used for women undergoing ovulation induction and multiple follicular development in those who are able to produce and release eggs (ovulate).
is a highly purified preparation of human follicle FSH, containing 75 IUs FSH with 2% luteinizing hormone (LH) activity. BRAVELLE® stimulates eggs to mature in women whose ovaries are basically healthy but are unable to develop eggs. It is not used by women who suffer from ovarian failure.
BRAVELLE® is usually used together with human chorionic gonadotropin (hCG), and is indicated for ovulation induction following pituitary suppression and multiple follicular development following pituitary suppression.
In assisted reproductive technology (ART), BRAVELLE has demonstrated safety and efficacy across a range of patient ages1 and types, including donor and high BMI patients.2,3
BRAVELLE® is available by prescription in 5mL vials containing 75 IU FSH with accompanying diluent.
Q•Cap™ is the only available vial adapter for needle-free reconstitution. It provides a convenient way to mix your medicines.
There are no additional administration methods to learn. Q•Cap™ eliminates stress, anxiety, and accidental needlesticks associated with traditional reconstitution, which increases your comfort level and that of your partner. And, importantly, Q•Cap™ helps build your confidence about reconstitution.
Q•Cap™ can only be used with Ferring fertility products, including BRAVELLE®, MENOPUR®, and REPRONEX®.
BRAVELLE® administered SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. BRAVELLE® administered SC or IM, in conjunction with hCG, is indicated for ovulation induction in patients who have previously received pituitary suppression.
Important Safety Information
Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe BRAVELLE®. BRAVELLE®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence 6.0%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. BRAVELLE® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; the presence of any cause of infertility other than anovulation; abnormal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to urofollitropins, purified. BRAVELLE® is contraindicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of BRAVELLE® when administered during pregnancy.
